In 2018, FDA approved atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin as the first-line treatment of metastatic non-squamous NSCLC with wild-type EGFR and ALK (68). This evidence concerns the gene EGFR and non-small cell lung carcinoma.